TAKE THIS POLL |
|
|
- Pipeline Insight - Molecular Targeted Cancer Therapies Can anything else revolutionize the market? - New 4 Jul 2008 18:17 GMT
... 2016. Among agents with the greatest commercial potential are the angiogenesis inhibitors Recentin (cediranib; AstraZeneca), aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) and pazopanib (GlaxoSmithKline). Other candidates holding particular promise include the only ...
- Insurers lead decline 4 Jul 2008 17:56 GMT
... (Wm) Supermarkets (MRW) 254.50p +2.83% Rio Tinto (RIO) 5,600.00p +2.56% Next (NXT) 873.00p +2.28% AstraZeneca (AZN) 2,356.00p +1.82% Xstrata (XTA) 3,764.00p +1.46% Cable & Wireless (CW.) 155.90p +1.37% Amec (AMEC) ...
- Friends Provident suffers Lombard blow 4 Jul 2008 17:56 GMT
... (Wm) Supermarkets (MRW) 254.50p +2.83% Rio Tinto (RIO) 5,600.00p +2.56% Next (NXT) 873.00p +2.28% AstraZeneca (AZN) 2,356.00p +1.82% Xstrata (XTA) 3,764.00p +1.46% Cable & Wireless (CW.) 155.90p +1.37% Amec (AMEC) ...
- Nordic shares close lower, led by banks after Goldman Sachs note UPDATE 4 Jul 2008 16:36 GMT
... Independence Day and high oil prices damped buying interest. Among the few risers were AstraZeneca -- up 2.55 percent at 281 Swedish crowns -- and Denmark's Vestas Wind Systems -- ...
- FDA Panel Recommends Safety Tests For New Diabetes Drugs 4 Jul 2008 14:57 GMT
... cost manufacturers millions but would definitely protect patients from unforeseen heart risks. GlaxoSmithKline PLC, AstraZeneca and Novartis AG are among the leading companies developing diabetes treatments to compete in the ...
- Shares off the bottom 4 Jul 2008 12:30 GMT
... FTSE 100 - Risers Next (NXT) 883.50p +3.51% Morrison (Wm) Supermarkets (MRW) 256.00p +3.43% AstraZeneca (AZN) 2,365.00p +2.20% British American Tobacco (BATS) 1,752.00p +2.16% Tesco (TSCO) 348.80p +2.14% Sage Group ...
- Alabama tells pharma firms to settle or face trial in Medicaid fraud cases 4 Jul 2008 11:36 GMT
... of Alabama’s bid to get compensation from the other 69 drugmakers (a case against AstraZeneca has already gone to trial) it sued as part of a Medicaid drug pricing fraud ...
- France's Cellectis gets cash boost from Regeneron settlement 4 Jul 2008 11:36 GMT
... However, those royalties will not extend to licence agreements Regeneron has in place with AstraZeneca, Astellas Pharma and Sanofi-Aventis. "Regeneron Pharmaceuticals is to fork out almost $12.5 million to ...
- Footsie recovers from early losses as banks strengthen 4 Jul 2008 10:35 GMT
... the year. That lifted shares 241/2p to 874p, almost 3 per cent. Drugs giant AstraZeneca also gained 81p to 2314p following a broker upgrade after its patent victory Wednesday. Rival ...
- Relapse Time Prolonged In Clinically Stable Patients With Bipolar I Disorder Treated With Quetiapine As Adjunct Therapy To Mood Stabilisers 4 Jul 2008 07:59 GMT
... AstraZeneca announced the online publication of long-term ® (quetiapine fumarate) clinical trial data in the Journal ...
- Banks boost Europe; euro down vs dollar 4 Jul 2008 06:32 GMT
... the advance in the broader market as investors switched into traditional safe haven assets. AstraZeneca, GlaxoSmithKline and Sanofi-Aventis rose between 2.6 and 3.7%, extending Wednesday’s rally. Meanwhile, the euro ...
- More tests urged for new drugs for diabetes 4 Jul 2008 04:34 GMT
... of Medicine. The FDA is not required to follow the panel's advice. GlaxoSmithKline PLC, AstraZeneca and Novartis AG are among the companies developing diabetes treatments to compete in the domestic ...
- FDA Panel Urges More Testing for Diabetes Drugs 4 Jul 2008 04:28 GMT
... to perform long-term studies that track heart problems in thousands of patients. GlaxoSmithKline PLC, AstraZeneca and Novartis AG are among the companies developing diabetes treatments to compete in the domestic ...
- FDA Panel Urges More Testing for Diabetes Drugs - July 03, 2008 4 Jul 2008 04:27 GMT
... to perform long-term studies that track heart problems in thousands of patients. GlaxoSmithKline PLC, AstraZeneca and Novartis AG are among the companies developing diabetes treatments to compete in the domestic ...
- require longer studies 4 Jul 2008 04:26 GMT
... to perform long-term studies that track heart problems in thousands of patients. GlaxoSmithKline PLC, AstraZeneca and Novartis AG are among the companies developing diabetes treatments to compete in the domestic ...
- AstraZeneca granted summary judgment in Seroquel patent litigation 4 Jul 2008 03:34 GMT
... AstraZeneca had sued Teva Pharmaceutical Industries and Sandoz, alleging infringement of AstraZeneca's patent as a result ...
- GlaxoSmithKline, Novartis to appeal $114 million verdict in Alabama drug price lawsuits 3 Jul 2008 23:59 GMT
... In the first trial in February, a jury awarded the state $215 million against AstraZeneca PLC. Montgomery County Circuit Judge Charles Price, who presided over both trials, later reduced that ...
- 2 drug firms to appeal $114M price fraud verdict 3 Jul 2008 22:56 GMT
... In the first trial in February, a jury awarded the state $215 million against AstraZeneca PLC. ( ) Montgomery County Circuit Judge Charles Price, who presided over both trials, later ...
- London shares close higher; banks gain; Wall Street positive UPDATE 3 Jul 2008 21:31 GMT
... 'outperform' rating on the group. Midcap VT closed up 17-1/2 at 631. Pharmaceutical giants AstraZeneca and GlaxoSmithKline also continued to attract buyers, taking on 81 at 2,314 and 35 at ...
- Bio-Pharma Launch Value Maximized Through New Product Commercialization Excellence 3 Jul 2008 20:22 GMT
... Product Commercialization Excellence. The benchmarking study included such influential companies as Abbott, Allergan, Amgen, AstraZeneca, Bayer, Eli Lilly, Genentech, GSK, Merck and Novartis. Key benchmark metrics and executive insights ...
1 - 25 of 368 next >
News by PR Newswire
|
